Leukemia Clinical Trials

Showing 661-680 of 5,235 trials

AVAILABLE

Managed Access Programs for ABL001, Asciminib

NCT04360005

The purpose of this registration form is to list all Managed Access Programs (MAPs) related to ABL001, asciminib

Chronic Myeloid Leukemia in Chronic Phase

Novartis Pharmaceuticals

RECRUITINGPHASE1

Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML

NCT05024552

This study combines vyxeos and gilteritinib in patients with relapsed or refractory FLT3-mutated acute myeloid leukemia. Vyxeos and gilteritinib will be given as induction therapy. Those patients entering a complete remission or a complete remission with incomplete blood count recovery will be allowed to proceed to consolidation therapy with vyxeos and gilteritinib. Those patients who do not proceed to an allogeneic stem cell transplant for any reason are able to enter the maintenance phase of this trial using daily gilteritinib

Acute Myeloid Leukemia With FLT3/ITD Mutation

H. Lee Moffitt Cancer Center and Research Institute22 participantsStarted Feb 2022

Tampa, Florida, United States

RECRUITINGPHASE2

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

NCT05168930

This study is being done to test the effectiveness of zanubrutinib in combination with venetoclax in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)

Dana-Farber Cancer Institute45 participantsStarted Feb 2022

Scarborough, Maine, United States • Boston, Massachusetts, United States • Boston, Massachusetts, United States +1 more locations

Managed Access Programs for ABL001, Asciminib

Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

Related Searches

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC).

Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA

Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy

Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma

UDOPAL Study: Home-Based Interventional Approach to Pain Management in Home-Hospitalized Patients

Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.

Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers

STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia

REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy

A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Abdominal Wall Tension in Patients Undergoing Ventral Hernia Repair Without Component Separation

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics

A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up

AI-Powered Fall Risk Prediction in Nursing Care